esophageal squamous cell carcinoma
Conditions
Interventions
experimental group:anlotinib combined with simultaneous radiotherapy and chemotherapy
controlled group:simultaneous radiotherapy and chemotherapy
Sponsors
Shandong Tumor Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Patients aged 18 to 80 years, male and female. 2) Pathological confirmed of esophageal squamous cell carcinoma; 3) TNM stage T3-4N0M0, TxN1-2M0, TxNxM1a (cervical lymph node metastasis); 4) Patients with expected survival >=6 months; 5) KPS >=70; 6) Hemoglobin >= 100g/L, platelet >=100 x 10^9/L, neutrophil >= 1.5x10^9/L; serum creatinine SCR 0.8L; 8) patients must sign informed consent form.
Exclusion criteria
Exclusion criteria: 1) There are contraindications to radiotherapy and chemotherapy (such as active infection, symptomatic heart disease within 6 months after myocardial infarction, including unstable angina pectoris, congestive heart failure or uncontrolled arrhythmia, immunosuppressive therapy); 2) The general condition of the patient is poor, and the KPS score less than 70; 3) Patients who have previously treated with thoracic radiotherapy; 4) Patients who complicate with other malignant tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| the incidence of radiation-induced lung injury; | — |
Countries
China
Contacts
Public ContactXudong Hu
Shandong Cancer Hospital
Outcome results
None listed